JP2021505545A - 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 - Google Patents

造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 Download PDF

Info

Publication number
JP2021505545A
JP2021505545A JP2020529342A JP2020529342A JP2021505545A JP 2021505545 A JP2021505545 A JP 2021505545A JP 2020529342 A JP2020529342 A JP 2020529342A JP 2020529342 A JP2020529342 A JP 2020529342A JP 2021505545 A JP2021505545 A JP 2021505545A
Authority
JP
Japan
Prior art keywords
a1at
hct
dose
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505545A5 (https=
Inventor
マルク・ウークニス
クリスティーネ・フォークト
ゴータム・バヘティ
ジョン・ロバーツ
Original Assignee
シーエスエル・ベーリング・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル・ベーリング・エルエルシー filed Critical シーエスエル・ベーリング・エルエルシー
Publication of JP2021505545A publication Critical patent/JP2021505545A/ja
Publication of JP2021505545A5 publication Critical patent/JP2021505545A5/ja
Priority to JP2023174014A priority Critical patent/JP2024001191A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2020529342A 2017-12-01 2018-11-30 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 Pending JP2021505545A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174014A JP2024001191A (ja) 2017-12-01 2023-10-06 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US62/593,446 2017-12-01
US201862729376P 2018-09-10 2018-09-10
US62/729,376 2018-09-10
PCT/US2018/063179 WO2019108865A1 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174014A Division JP2024001191A (ja) 2017-12-01 2023-10-06 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法

Publications (2)

Publication Number Publication Date
JP2021505545A true JP2021505545A (ja) 2021-02-18
JP2021505545A5 JP2021505545A5 (https=) 2022-01-06

Family

ID=64734181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529342A Pending JP2021505545A (ja) 2017-12-01 2018-11-30 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
JP2023174014A Pending JP2024001191A (ja) 2017-12-01 2023-10-06 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174014A Pending JP2024001191A (ja) 2017-12-01 2023-10-06 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法

Country Status (13)

Country Link
US (2) US11857610B2 (https=)
EP (2) EP4321220B1 (https=)
JP (2) JP2021505545A (https=)
AU (1) AU2018374285B2 (https=)
DK (1) DK3716998T3 (https=)
ES (2) ES2975208T3 (https=)
FI (1) FI3716998T3 (https=)
HR (1) HRP20240475T8 (https=)
HU (1) HUE066011T2 (https=)
PL (1) PL3716998T3 (https=)
PT (1) PT3716998T (https=)
SI (1) SI3716998T1 (https=)
WO (1) WO2019108865A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045449A1 (en) * 2005-06-07 2012-02-23 Dinarello Charles A Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
JP2014519852A (ja) * 2011-06-24 2014-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト アルファ−１抗トリプシン融合分子のための組成物、方法および使用
WO2017117558A1 (en) * 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120045449A1 (en) * 2005-06-07 2012-02-23 Dinarello Charles A Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
JP2014519852A (ja) * 2011-06-24 2014-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト アルファ−１抗トリプシン融合分子のための組成物、方法および使用
WO2017117558A1 (en) * 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD (2014) VOL.124, ISSUE 21, 3927, JPN6022041007, ISSN: 0005076766 *
PROC. NATL. ACAD. SCI. U.S.A., (2012) VOL.109, NO.2, P.564-569, JPN6022041006, ISSN: 0004888295 *

Also Published As

Publication number Publication date
HRP20240475T8 (hr) 2024-08-02
SI3716998T1 (sl) 2024-05-31
EP3716998B1 (en) 2024-01-10
PT3716998T (pt) 2024-04-09
EP4321220B1 (en) 2025-10-29
DK3716998T3 (da) 2024-04-02
JP2024001191A (ja) 2024-01-09
PL3716998T3 (pl) 2024-06-24
US20210008182A1 (en) 2021-01-14
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
HUE066011T2 (hu) 2024-07-28
AU2018374285B2 (en) 2024-06-27
ES3059603T3 (en) 2026-03-23
HRP20240475T1 (hr) 2024-07-05
AU2018374285A1 (en) 2020-07-02
WO2019108865A1 (en) 2019-06-06
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
FI3716998T3 (fi) 2024-04-16
EP3716998A1 (en) 2020-10-07
ES2975208T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
US20240190984A1 (en) Methods of treating multiple myeloma
AU2016250388A1 (en) Treatment for rheumatoid arthritis
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
KR20220008305A (ko) 다발성 골수종을 치료하기 위해서 항-cd38 항체를 투여하는 방법
WO2021223048A1 (zh) 抗体药物偶联物及其制剂
CN114502241A (zh) 抗半乳凝素-9抗体和化疗剂的联合癌症疗法
JP2024001191A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
Llop-Guevara et al. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
CN116782934A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
JP2024534926A (ja) 寛容性を誘導するための方法及び組成物
US20250228942A1 (en) Methods for activation and expansion of engineered natural killer cells and combinations with antibodies
EP2373339B1 (en) A b cell depleting agent for the treatment of atherosclerosis
HK40106704A (en) A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
Pilch et al. Monoclonal antibodies in solid organ transplantation
RU2838203C2 (ru) Способы лечения множественной миеломы
Snowden et al. Haemopoietic Stem Cell Transplantation for Rheumatoid Arthritis—World Experience and Future Trials
TW202602494A (zh) 格菲妥單抗與化學療法之組合治療
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
Chen et al. Highlights in Graft-vs-Host Disease From the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR
US20060110396A1 (en) Use of ligands of the antigen CDw52 for the treatment of diseases that are related to degenerated macrophages
Scheinberg et al. CLINICAL RESEARCH PROJECT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606